Independent product information • Affiliate-supported • Last updated
Independent EndoPeak research

Epimedium / Horny Goat Weed: Evidence and Safety

Epimedium is often marketed for sexual performance, but much of the mechanistic discussion around icariin should not be confused with finished-product clinical proof.

Reviewed and updated: September 12, 2026
EndoPeak label 33.3 mg per EndoPeak serving. Independent research This guide discusses the ingredient literature separately from the finished product.

What Epimedium is

Epimedium is a genus of plants often sold under the common name horny goat weed. The current EndoPeak label lists 33.3 mg of Epimedium aerial parts, identified as Epimedium sagittatum, per serving.

Researchers frequently discuss icariin and related flavonoids when explaining potential mechanisms. A retail herb amount does not necessarily tell us how much icariin is present.

Mechanistic evidence is not the same as a clinical outcome

Laboratory and animal studies can help identify biochemical pathways worth investigating. They are useful for hypothesis generation, but they do not show that a human taking a specific EndoPeak serving will experience a particular erectile or libido effect.

Clinical claims should be based on appropriately designed human studies of a relevant product and dose.

Why standardization matters

Two Epimedium products can have the same milligram number yet contain different concentrations of active constituents because species, plant part, extraction and standardization differ.

The EndoPeak label identifies the species and aerial parts but does not present a standardized icariin percentage on the panel supplied for this build.

Safety and expectations

People using medication or living with cardiovascular or other chronic conditions should treat performance-oriented botanicals cautiously and follow the product warning to seek professional guidance.

A responsible evidence summary therefore avoids promising stronger erections or treatment of erectile dysfunction from the ingredient alone.

Finished-product boundary: Ingredient research does not prove that the complete EndoPeak formula produces the same effects. We did not identify a peer-reviewed randomized controlled trial of the finished EndoPeak formula during this build.

References

  1. Epimedium/icariin review — Review of pharmacology and clinical context.
  2. Systematic review of male supplement ingredients — Broader context for evidence behind marketed ingredients.